Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979505 · ClinicalTrials.gov registry record · Phase 2
GV101 in Healthy Obese Participants
A Phase 2 study of Weight Management, sponsored by Graviton Bioscience Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 20
- Study locations
NCT06979505 is a Phase 2 study of Weight Management that has completed, run by Graviton Bioscience Corporation. The registered enrollment target is 131 participants, below the 852-participant average among 8 other Weight Management trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06979505, a Phase 2 study of Weight Management, has completed, sponsored by Graviton Bioscience Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.
Conditions Studied
Interventions
- DRUG GV101
- DRUG GV101 placebo
Study Locations (20)
Israel
- Hadassah Medical Center Ein Karem - Jerusalem
- Hasharon Hospital - Petah Tikva
- Rabin Medical Center, Beilinson Hospital - Petah Tikva
- Sheba Medical Center - Tel Litwinsky
California
- Catalina Research Institute, LLC - Montclair
- Encompass Clinical Research - Spring Valley
Missouri
- Study Metrix Research - City of Saint Peters
- Kansas City Research Institute - Kansas City
Utah
- Advanced Research Institute - Ogden - Ogden
- Chrysalis Clinical Research - St. George
Alabama
- Lakeview Clinical Research, LLC - Guntersville
Arizona
- Arizona Clinical Trials - Tucson
Kentucky
- Louisville Metabolic and Atherosclerosis Research Center (L-MARC) - Louisville
Louisiana
- Tandem Clinical Research - Marrero
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2026-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06979505
The ClinicalTrials.gov registry entry for NCT06979505 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 852-participant average among 8 other Weight Management trials with a reported enrollment target (85% lower). The listed sponsor is Graviton Bioscience Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Weight Management appearing as the primary indexed condition, and to 2 interventions - of which GV101 is the first listed.
NCT06979505 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Israel, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06979505 about?
NCT06979505 is a clinical study titled "GV101 in Healthy Obese Participants". The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.
What is the current status of trial NCT06979505?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2025-06-30. Estimated completion is 2026-01-28.
What conditions does trial NCT06979505 study?
This clinical trial studies the following conditions: Weight Management.
What interventions are being tested in trial NCT06979505?
The interventions under investigation include: GV101 (DRUG), GV101 placebo (DRUG).
Who is sponsoring clinical trial NCT06979505?
This trial is sponsored by Graviton Bioscience Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06979505 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
COMPLETED · Phase 2
-
Weight Loss Management in Endometrial Cancer Survivors
RECRUITING
-
Advancing Biopsychosocial Care Training Initiative
RECRUITING · NA
-
How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types
RECRUITING · NA
-
Weight Management After Cancer for Survivors in Rural Communities
RECRUITING · NA
-
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.